Targeting mechanisms that cause prostate cancer to resist treatment
Overcoming mechanisms of PTPN1 driving therapy- and castration- resistant prostate cancer with novel theranostics
This study is looking at how a specific protein might help prostate cancer become harder to treat after hormone therapy, with the hope of finding new ways to improve treatment for patients facing this tough challenge.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-11020113 on NIH RePORTER |
What this research studies
This research investigates the molecular mechanisms behind therapy- and castration-resistant prostate cancer (t-CRPC), which is a major cause of mortality in prostate cancer patients. The study focuses on the role of the protein tyrosine phosphatase non-receptor 1 (PTPN1) in the transition of androgen-dependent prostate cancer cells to a more aggressive neuroendocrine phenotype. By using tissue culture and animal models, the researchers aim to understand how anti-androgen therapies influence PTPN1 expression and contribute to treatment resistance. The ultimate goal is to identify new therapeutic targets that could improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those who have developed resistance to hormonal therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone hormonal therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that prolong survival for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promise in targeting molecular mechanisms in prostate cancer, but this specific approach focusing on PTPN1 is relatively novel.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: Hsieh, Jer-Tsong — Ut Southwestern Medical Center
- Study coordinator: Hsieh, Jer-Tsong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.